Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Double-blind, Randomized, Placebo-controlled, Multicentre Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TAK-242 and (G-CSF) in Subjects With (sAH) and (ACLF)

NCT06890039 is registered in ClinicalTrials.gov with Yaqrit Ltd as lead sponsor.

NCT NCT06890039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06890039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Double-blind, Randomized, Placebo-controlled, Multicentre Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TAK-242 and (G-CSF) in Subjects With (sAH) and (ACLF)
Lead sponsor
Yaqrit Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
June 29, 2026
Completion date
December 31, 2028
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute-on-chronic liver failure, alcoholic hepatitis, liver cirrhosis, alcoholic